Ticker Scorecard - HALO Basics Company: Halozyme Therapeutics, Inc. IPO Date: March 16, 2004 Sector: Healthcare Industry: Biotech Market Cap: $7.35B Activated in VL: True Average Daily Range Avg Daily Range: $0.36 | 2.17% Avg Daily Range (30 D): $0.58 | 1.03% Avg Daily Range (90 D): $0.74 | 1.42% Institutional Daily Volume Avg Daily Volume: .93M Avg Daily Volume (30 D): 1.05M Avg Daily Volume (90 D): 1.21M Trade Size Avg Trade Size (Sh.): 112 Avg Trade Size (Sh.) (30 D): 55 Avg Trade Size (Sh.) (90 D): 60 Institutional Trades Total Inst.Trades: 8,229 Avg Inst. Trade: $2.55M Avg Inst. Trade (30 D): $3.05M Avg Inst. Trade (90 D): $3.04M Avg Inst. Trade Volume: .08M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $4.66M Avg Closing Trade (30 D): $10.36M Avg Closing Trade (90 D): $11.25M Avg Closing Volume: 147.85K     News Nov 11, 2024 @ 4:59 PM Needle Free Injectors Market Is Expected To Reach ... Source: Dimension Market Research Jun 27, 2024 @ 1:50 PM Why This 1 Momentum Stock Could Be a Great Additio... Source: Zacks Equity Research Jun 20, 2024 @ 1:45 PM Are You a Growth Investor? This 1 Stock Could Be t... Source: Zacks Equity Research Jun 17, 2024 @ 1:40 PM Here's Why Halozyme Therapeutics (HALO) is a Stron... Source: Zacks Equity Research Jun 14, 2024 @ 3:30 PM Why Is Kodiak Sciences (KOD) Down 26.2% Since Last... Source: Zacks Equity Research Financials   TTM Q4 2024 FY 2024 Basic EPS $3.5 $1.08 $3.5 Diluted EPS $3.43 $1.06 $3.43 Revenue $ 1.02B $ 298.01M $ 1.02B Gross Profit $ 855.91M $ 255.95M $ 855.91M Net Income / Loss $ 444.09M $ 137.01M $ 444.09M Operating Income / Loss $ 551.48M $ 175.5M $ 551.48M Cost of Revenue $ 159.42M $ 42.06M $ 159.42M Net Cash Flow $ -2.52M $ -38.47M $ -2.52M PE Ratio 16.59